Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicines Australia Chair Retires

This article was originally published in Scrip

Executive Summary

Medicines Australia's chair, Dr. Martin Cross, will be retiring from the board after nearly 30 years in the pharmaceutical industry – effective Oct. 20, 2015. Cross was appointed Medicines Australia's chair in 2013, joining the industry association from Alphapharm, where he was managing director. Under his leadership came the development of COMPARE, a new regular industry report; the re-launch of the Access to Medicines working group and consultation; as well as authorization and implementation of the 18th edition of the Code of Conduct which encompasses a sector-leading transparency. As his exit from Medicine's Australia approaches, Cross has expressed his biggest concerns for the industry. He highlighted the effect of budget related cuts on the sector and his disappointment of failing to come to a strategic agreement with the government before his retirement. Medicines Australia's new board and replacement chair will be announced on 20th October at the association's annual general meeting.

You may also be interested in...



Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.

Topics

UsernamePublicRestriction

Register

SC030028

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel